Skip to main content
NeopharmCO.,LTD. logo

NeopharmCO.,LTD. — Investor Relations & Filings

Ticker · 092730 ISIN · KR7092730001 KO Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2022-08-05 Earnings Release
Country KR South Korea
Listing KO 092730

About NeopharmCO.,LTD.

https://neopharm.co.kr

Neopharm is a science-based company specializing in the development, manufacturing, and sale of dermatological skincare and cosmetic products. A pioneer in skin barrier research, the company focuses on restoring skin homeostasis. Its core innovation is the proprietary Multi-Lamellar Emulsion (MLE) technology, which mimics the natural lipid structure of the skin to repair and strengthen its protective functions. The company's primary product lines, including the flagship brand Atopalm, are specifically formulated for sensitive, dry, and compromised skin. These non-steroid solutions are grounded in dermatological science to address various skin concerns.

Recent filings

Filing Released Lang Actions
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Neopharm, detailing quarterly financial highlights such as revenue, operating profit, and net income. It is a short, structured announcement of financial results rather than a full annual or interim report. According to the filing definitions, this fits the 'Earnings Release' (ER) category as it provides key financial highlights for the period. Q2 2022
2022-08-05 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'NeoPharm' (주식회사 네오팜) covering the period from January 1, 2022, to March 31, 2022. It contains detailed financial information, business operations, management discussions, and capital structure data, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-13 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Release' (잠정실적) for Neopharm, detailing quarterly financial performance (revenue, operating profit, net income) for the period 2022.01.01 to 2022.03.31. It provides key financial highlights rather than a full comprehensive report, fitting the definition of an Earnings Release (ER). Q1 2022
2022-05-06 Korean
[기재정정]현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory filing from Neopharm regarding a 'Cash/In-kind Dividend Decision' (현금ㆍ현물배당 결정). It details the dividend amount per share, the dividend payment date, and the record date. Since the primary purpose of the document is to announce the specific details and payment schedule of a dividend to shareholders, it falls under the 'Notice of Dividend Amount' category.
2022-04-06 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend declarations, and the election of board members and audit committee members. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2022-03-24 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the reappointment of specific outside directors for Neopharm. This falls directly under the category of announcements regarding changes in the company's board of directors or senior management.
2022-03-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.